SERES THERAPEUTICS INC (MCRB) Stock Earnings & Estimates
USA - NASDAQ:MCRB - US81750R2013 - Common Stock
28.63 USD
+3.92 (+15.86%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 34.505M 22.07% | 33.215M -3.74% | 144.927M 336.33% | 10.929M -100.00% | 128.59M | ||||||||
| EBITDA YoY % growth | -62.781M 32.07% | -81.552M -29.90% | -58.546M 28.21% | -242.909M -195.98% | -118.514M -5.75% | -119.267M 38.56% | -81.6M 27.52% | -85.68M -5.00% | -86.7M -1.19% | N/A | N/A | N/A | |
| EBIT YoY % growth | -70.384M 29.82% | -88.13M -25.21% | -64.493M 26.82% | -234.172M -178.97% | -124.964M -5.32% | -125.264M 37.70% | -102.442M 13.22% | -93.63M 8.60% | -91.52M 2.25% | -87.006M 4.93% | -87.006M | -87.006M | |
| Operating Margin | -203.98% | -265.33% | -44.50% | -2,142.67% | -97.18% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | -26.20 46.09% | -23.00 12.21% | -14.40 37.39% | -45.91 -225.00% | -20.14 61.54% | -2.18 -7.78% | 0.10 100.51% | -10.54 -10,808.11% | -10.41 1.24% | 3.60 134.59% | N/A | N/A |
All data in USD
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -2.18 -8.97% | -2.03 31.25% | -2.93 -28.96% | -2.98 -416.85% | -3.12 -43.21% |
| Revenue Q2Q % growth | -100.00% | ||||
| EBITDA Q2Q % growth | -27.54M -17.86% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -21.683M 24.80% | -22.542M 17.23% | -26.52M -6.59% | -27.03M -20.26% | -28.56M -31.72% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2025 Q2Q % growth | 0.94 112.37% | 1.31 | -0.37 | -28.00% |
| Q2 2025 Q2Q % growth | -2.27 48.41% | -2.54 | 0.27 | 10.71% |
| Q1 2025 Q2Q % growth | -2.96 45.19% | -0.55 | -2.41 | -437.40% |
| Q4 2024 Q2Q % growth | -2.00 68.75% | -4.02 | 2.02 | 50.19% |
| Q3 2024 Q2Q % growth | -7.60 -2.70% | -5.01 | -2.59 | -51.81% |
| Q2 2024 Q2Q % growth | -4.40 -161.11% | -5.59 | 1.19 | 21.28% |
| Q1 2024 Q2Q % growth | -5.40 52.63% | -6.95 | 1.55 | 22.33% |
| Q4 2023 Q2Q % growth | -6.40 40.74% | -10.14 | 3.74 | 36.89% |
| Q3 2023 Q2Q % growth | -7.40 24.49% | -10.23 | 2.83 | 27.66% |
| Q2 2023 Q2Q % growth | 7.20 151.43% | 10.89 | -3.69 | -33.89% |
| Q1 2023 Q2Q % growth | -11.40 6.56% | -11.20 | -0.20 | -1.81% |
| Q4 2022 Q2Q % growth | -10.80 -3.85% | -9.49 | -1.31 | -13.85% |
| Q3 2022 Q2Q % growth | -9.80 -168.06% | -9.56 | -0.24 | -2.48% |
| Q2 2022 Q2Q % growth | -14.00 -32.08% | -12.16 | -1.84 | -15.12% |
| Q1 2022 Q2Q % growth | -12.20 -56.41% | -10.69 | -1.51 | -14.08% |
| Q4 2021 Q2Q % growth | -10.40 -126.09% | -8.91 | -1.49 | -16.75% |
| Q3 2021 Q2Q % growth | 14.40 300.00% | -9.44 | 23.84 | 252.50% |
| Q2 2021 Q2Q % growth | -10.60 -89.29% | -7.59 | -3.01 | -39.68% |
| Q1 2021 Q2Q % growth | -7.80 -39.29% | -6.31 | -1.49 | -23.61% |
| Q4 2020 Q2Q % growth | -4.60 8.00% | -5.71 | 1.11 | 19.43% |
| Q3 2020 Q2Q % growth | -7.20 -56.52% | -5.20 | -2.00 | -38.33% |
| Q2 2020 Q2Q % growth | -5.60 -16.67% | -5.27 | -0.33 | -6.34% |
| Q1 2020 Q2Q % growth | -5.60 52.54% | -5.73 | 0.13 | 2.31% |
| Q4 2019 Q2Q % growth | -5.00 | -5.68 | 0.68 | 11.94% |
| Q3 2019 Q2Q % growth | -4.60 | -6.55 | 1.95 | 29.75% |
| Q2 2019 Q2Q % growth | -4.80 | -9.88 | 5.08 | 51.42% |
| Q1 2019 Q2Q % growth | -11.80 | -8.07 | -3.73 | -46.30% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2025 Q2Q % growth | 10.2M | -10.2M | -100.00% | |
| Q4 2024 Q2Q % growth | -100.00% | % | ||
| Q3 2024 Q2Q % growth | -100.00% | % | ||
| Q2 2024 Q2Q % growth | -100.00% | % | ||
| Q1 2024 Q2Q % growth | 100.00% | 255K | -255K | -100.00% |
| Q4 2023 Q2Q % growth | 64K | 357K | -293K | -82.07% |
| Q3 2023 Q2Q % growth | 310K -91.00% | 870.06K | -560.06K | -64.37% |
| Q2 2023 Q2Q % growth | 126.473M 10,300.74% | 128.11M | -1.637M | -1.28% |
| Q1 2023 Q2Q % growth | -522K -134.96% | 1.412M | -1.934M | -136.97% |
| Q4 2022 Q2Q % growth | -100.00% | 6.118M | -6.118M | -100.00% |
| Q3 2022 Q2Q % growth | 3.444M -97.28% | 7.144M | -3.7M | -51.79% |
| Q2 2022 Q2Q % growth | 1.216M -76.90% | 5.078M | -3.862M | -76.05% |
| Q1 2022 Q2Q % growth | 1.493M -73.89% | 8.649M | -7.156M | -82.74% |
| Q4 2021 Q2Q % growth | 7.221M -58.89% | 12.499M | -5.278M | -42.23% |
| Q3 2021 Q2Q % growth | 126.725M 8,843.19% | 7.462M | 119.263M | 1,598.27% |
| Q2 2021 Q2Q % growth | 5.263M -12.94% | 5.503M | -240K | -4.36% |
| Q1 2021 Q2Q % growth | 5.718M -30.17% | 6.579M | -861K | -13.09% |
| Q4 2020 Q2Q % growth | 17.564M 130.44% | 7.07M | 10.494M | 148.43% |
| Q3 2020 Q2Q % growth | 1.417M -79.85% | 7.423M | -6.006M | -80.91% |
| Q2 2020 Q2Q % growth | 6.045M -51.76% | 9.735M | -3.69M | -37.90% |
| Q1 2020 Q2Q % growth | 8.189M 11.86% | 8.701M | -512K | -5.88% |
| Q4 2019 Q2Q % growth | 7.622M | 6.376M | 1.246M | 19.54% |
| Q3 2019 Q2Q % growth | 7.031M | 6.833M | 198K | 2.90% |
| Q2 2019 Q2Q % growth | 12.531M | 8.291M | 4.24M | 51.14% |
| Q1 2019 Q2Q % growth | 7.321M | 15.619M | -8.298M | -53.13% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 4.5% | 8.79% | -67.99% | 105.77% |
| Revenue | N/A | N/A | N/A | N/A |